By Mill Chart
Last update: Aug 4, 2025
KRYSTAL BIOTECH INC (NASDAQ:KRYS) reported second-quarter 2025 financial results, with revenue and earnings per share (EPS) surpassing analyst expectations. The company’s performance, particularly in its flagship product VYJUVEK, drove the beat, while the market reaction reflects optimism as shares rose nearly 4% in pre-market trading.
The outperformance suggests robust demand for VYJUVEK, a gene therapy treatment for dystrophic epidermolysis bullosa (DEB), which recently gained approval in Japan for use in patients from birth.
The positive earnings surprise appears to have bolstered investor confidence:
Key takeaways from Krystal Biotech’s Q2 2025 update include:
Analysts forecast full-year 2025 revenue at $407 million, with Q3 estimates aligning with sequential growth. The lack of company-provided outlook does not appear to have dampened sentiment, as the market seems to be pricing in continued execution on VYJUVEK’s global rollout.
For more detailed earnings estimates and historical performance, see Krystal Biotech’s earnings data.
Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.
156.98
+3.11 (+2.02%)
Find more stocks in the Stock Screener